Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid as adjuvant therapy in neovascular Age-related Macular Degeneration (Z-AMD)
2019-001492-37Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of zoledronic acid in exudative macular degeneration (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Mean change in best-corrected visual acuity (BCVA). Started May 2019; status: completed.
02
Drugs
zoledronic acid
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-001492-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001492-37.